|
11 Nov 2019
|
FDC
|
Rudra Shares and Stock Brokers Ltd
|
438.90
|
220.00
|
180.50
(143.16%)
|
Target met |
Buy
|
|
|
Forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmic & First in South East Asia to offer ophthalmic formulations, using Blow-Fill-Seal (BFS) technology. FDC is a fundamentally strong company with huge cash in its balance sheet. The company has good product profile starting with Electral which is the market leader in the ORS segment. Moreover, company continues to report decent operating margins and generates sufficient free cash flow from operations every year where part has been used for buyback in the past, for...
|
|
07 Aug 2018
|
FDC
|
ICICI Securities Limited
|
438.90
|
325.00
|
244.00
(79.88%)
|
|
Buy
|
|
|
|
|
21 Aug 2017
|
FDC
|
Choice India
|
438.90
|
205.00
|
170.25
(157.80%)
|
Target met |
Buy
|
|
|
FDC Limited (Food, Drugs and Chemicals) is a fully integrated pharmaceutical company which has been in business for more than 70 years. The company is engaged in manufacturing of specialized formulations and oral rehydration salts (ORS) since 1972. The company is currently ranked 26th in India as per AWACS-AIOCD, recording a growth of 3.7% and attaining a market share of 0.89% whereas IPM (Indian Pharmaceutical markets) recorded a growth of 10.3% as per secondary sales, as of March 2017. The Company has built a visible presence across markets in Europe, USA, Asia, Africa, Latin America and Confederation of Independent States (CIS). It has...
|
|
05 Dec 2016
|
FDC
|
HDFC Securities
|
438.90
|
255.00
|
223.30
(96.55%)
|
|
Buy
|
|
|
BUY FDC Ltd between Rs. 192 - 218, for the Target Price of Rs. 255 - 290
|
|
31 Dec 2013
|
FDC
|
Ashika Research
|
438.90
|
170.00
|
129.40
(239.18%)
|
Target met |
Buy
|
|
|
bulk drugs. The therapeutic segment consists of products such formulations, antioxidants and haematinics. But FDC is best known for its oral re-hydration salts (ORS) sold under the brand...
|